- Home
- Products
- Customized ADCs
- FAP
- Anti-FAP-SMCC-DM1 ADC
Anti-FAP-SMCC-DM1 ADC (CAT#: ADC-W-593)
This ADC product is comprised of an anti-FAP monoclonal antibody conjugated via a SMCC linker to DM1. The DM1 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, DM1 binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.
- ADC Target
- ADC Antibody
- ADC Linker
- ADC payload drug
- Name
- FAP
- Alternative Names
- FAP; fibroblast activation protein, alpha; FAPA; SIMP; DPPIV; prolyl endopeptidase FAP; seprase; FAPalpha; dipeptidyl peptidase FAP; surface-expressed protease; post-proline cleaving enzyme; gelatine degradation protease FAP; integral membrane serine prot
- Target Entrez Gene ID
- 2191
- Target UniProt ID
- B4DLR2
- Overview
- The protein encoded by this gene is a homodimeric integral membrane gelatinase belonging to the serine protease family. It is selectively expressed in reactive stromal fibroblasts of epithelial cancers, granulation tissue of healing wounds, and malignant cells of bone and soft tissue sarcomas. This protein is thought to be involved in the control of fibroblast growth or epithelial-mesenchymal interactions during development, tissue repair, and epithelial carcinogenesis. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.
- Overview
- Anti-FAP Antibody
- Species Reactivity
- Human
- Name
- SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate)
- Description
- Disulfide Linkers, are extensively exploited as a chemically labile linkage. Since the release of disulfide-linked drugs requires a cytoplasmic thiol cofactor, such as glutathione (GSH). Disulfides maintain stable at physiological pH and only when ADCs are internalized inside cells, the cytosol provides reducing environment including intracellular enzyme protein disulfide isomerase, or similar enzymes, drugs can be released.
- Name
- DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
- Description
- Derived from Maytansinoid,a group of cytotoxins structurally similar to rifamycin, geldanamycin, and ansatrienin. The eponymous natural cytotoxic agent maytansine is a 19-member lactam (ansa
macrolide) structure originally isolated from the Ethiopian shrub Maytenus ovatus. Maytansinoids can bind to tubulin at or near the vinblastine-binding site, which interfere the formation of microtubules and depolymerize already formed microtubules, inducing mitotic arrest in the intoxicated cells.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-EGFR (Imgatuzumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-1069)
- Anti-ERBB2 (Pertuzumab)-SMCC-DM1 ADC (CAT#: ADC-W-1112)
- Anti-TPBG-AcBut-CalichDMH ADC-12 (CAT#: ADC-W-197)
- Anti-CA9 (Girentuximab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-745)
- Anti-CD40LG (Toralizumab)-SPDB-DM4 ADC (CAT#: ADC-W-921)
- Anti-IL5 (Reslizumab)-SMCC-DM1 ADC (CAT#: ADC-W-1394)
- Anti-ITGAV (Intetumumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-1495)
- Anti-OxLDL-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-2093)
- Anti-CD248 (Ontuxizumab)-MC-MMAF ADC (CAT#: ADC-W-808)
- Anti-ITGAE-Mc-VC-PABC-MMAE ADC-1 (CAT#: ADC-W-532)
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-W-593. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
Same Linker
Same Payload
| CAT# | Product Name | Linker | Payload |
| ADC-W-1134 | Anti-FAP (Sibrotuzumab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
| ADC-W-1131 | Anti-FAP (Sibrotuzumab)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
| ADC-W-1130 | Anti-FAP (Sibrotuzumab)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
| ADC-W-1132 | Anti-FAP (Sibrotuzumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-1133 | Anti-FAP (Sibrotuzumab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
| CAT# | Product Name | Linker | Payload |
| ADC-W-473 | Anti-CD37-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
| ADC-W-496 | Anti-EGFR-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
| ADC-W-2583 | Anti-EGFR (Zalutumumab)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
| ADC-W-479 | Anti-CD74-SMCC-Dox ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | Doxorubicin |
| ADC-W-2610 | Anti-MS4A1 (Rituximab)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
| CAT# | Product Name | Linker | Payload |
| ADC-AA-050 | Protein G-MCC-DM1 ADC | MCC (Maleimidomethyl cyclohexane-1-carboxylate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
| ADC-AA-031 | anti-MIgG(Fc)Fab-N-DM1 ADC | Noncleavable linkers | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
| ADC-AA-054 | Protein A-MCC-DM1 ADC | MCC (Maleimidomethyl cyclohexane-1-carboxylate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
| ADC-W-603 | Anti-FOLH1-SMCC-DM1 ADC-3 | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
| ADC-W-541 | Anti-CD44-DM1 ADC | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.